Cuprina Holdings (Cayman) Limited Class A Ordinary Shares (CUPR) - Total Liabilities

Latest as of March 2026: $3.45 Million USD

Based on the latest financial reports, Cuprina Holdings (Cayman) Limited Class A Ordinary Shares (CUPR) has total liabilities worth $3.45 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Cuprina Holdings (Cayman) Limited Class long-term investment intensity to see how much of total assets are deployed in long-term investments.

Cuprina Holdings (Cayman) Limited Class A Ordinary Shares - Total Liabilities Trend (2021–2025)

This chart illustrates how Cuprina Holdings (Cayman) Limited Class A Ordinary Shares's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see how large is Cuprina Holdings (Cayman) Limited Class 's balance sheet.

Cuprina Holdings (Cayman) Limited Class A Ordinary Shares Competitors by Total Liabilities

The table below lists competitors of Cuprina Holdings (Cayman) Limited Class A Ordinary Shares ranked by their total liabilities.

Company Country Total Liabilities
Veganz Group AG
F:VEZ
Germany €20.64 Million
Fimperkasa Utama Tbk PT
JK:FIMP
Indonesia Rp5.07 Billion
Thai Polycons Public Company Limited
BK:TPOLY
Thailand ฿5.87 Billion
Hedera Group publ AB
ST:HEGR
Sweden Skr122.20 Million
NO GRAVITY GAMES ZY -10
F:8YX
Germany €776.14K
ModuLink Inc.
NASDAQ:MDLK
USA $775.74K
MTI Investment SE
ST:MTI
Sweden Skr24.45 Million
TAURUS ENERGY AB B SK120
F:8LU
Germany €10.84 Million

Liability Composition Analysis (2021–2025)

This chart breaks down Cuprina Holdings (Cayman) Limited Class A Ordinary Shares's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Cuprina Holdings (Cayman) Limited Class (CUPR) net asset quality to measure how much of total assets are equity-financed.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 2.35 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.68 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.41 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Cuprina Holdings (Cayman) Limited Class A Ordinary Shares's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Cuprina Holdings (Cayman) Limited Class A Ordinary Shares (2021–2025)

The table below shows the annual total liabilities of Cuprina Holdings (Cayman) Limited Class A Ordinary Shares from 2021 to 2025.

Year Total Liabilities Change
2025-12-31 $3.45 Million -44.41%
2024-12-31 $6.20 Million +38.41%
2023-12-31 $4.48 Million +39.46%
2022-12-31 $3.21 Million +96.41%
2021-12-31 $1.64 Million --

About Cuprina Holdings (Cayman) Limited Class A Ordinary Shares

NASDAQ:CUPR USA Medical Instruments & Supplies
Market Cap
$1.59 Million
Market Cap Rank
#30318 Global
#6167 in USA
Share Price
$1.73
Change (1 day)
+8.12%
52-Week Range
$0.25 - $8.41
All Time High
$9.40
About

Cuprina Holdings (Cayman) Limited, a biomedical and biotechnology company, focuses on the development and commercialization of products for the management of chronic wounds. The company manufactures and distributes a line of medical grade sterile blowfly larvae bio-dressing products used as a biological debridement tool for chronic wounds under the MEDIFLY brand name. It is also developing collag… Read more